Identificación del virus del papiloma humano (VPH) en diferentes muestras de pacientes con diagnóstico de lesiones de alto grado en cuello uterino. Estudio piloto en una población colombiana

Identificación del virus del papiloma humano (VPH) en diferentes muestras de pacientes con diagnóstico de lesiones de alto grado en cuello uterino. Estudio piloto en una población colombiana

Introduction: The Human Papilloma Virus (HPV) is relevant in the development of cervical cancer, a situation that has led to screening with cervical-uterine cytology and DNA-HPV molecular test that allows the early detection of a risk of developing this pathology in women. Although the incidence and mortality have decreased, science could not eradicate this disease. Objective: Identified HPV in different samples of patients diagnosed with preneoplastic lesions and cervical-uterine cancer. Methodology: Patients with high-grade lesions (LEI-AG) and/or carcinoma on cervical cytology and/or biopsy were included. A blood sample was taken from all of them, the availability of paraffin tissue (FFPE) was evaluated, and PCR genotyping for HPV was performed. Results: 27% (3) LEI-AG were between 30-39 years old and 9% (1) were under 29; 50% (6) were positive for HR-HPV other than 16-18 in liquid-based cytology (CBL) and 16% (1) negative. DNA was obtained from 100% of the FFPE, with positivity in 67% (6), 2 (33%) for HPV-16 and 4 (67%) for others (56, 58 and 68). 1 (11%) presented coinfection with HPV-56 and 58. 67% (4) showed concordance between CBL and FFPE; 1 was CBL negative and HPV-56 positive on FFPE and 1 was CBL HPV-18 positive and FFPE negative. No HPV positivity was obtained in the plasma samples tested. Conclusion: The relationship HPV and cervical-uterine cancer requires to work out in regional studies that allow to understand and to reassess the policies that are currently implemented in the country.

1. Lara Gutiérrez D, Mélida R, Mora S. Tratamientos alternativos de medicina tradicional para Chlamydia trachomatis, agente causal de una infección asintomática. NOVA. 2018;13(30):65-74.
2. https://doi.org/10.22490/24629448.2836
4. Fernandes A, Viveros-Carreño D, Hoegl J, Ávila M, Pareja R. Human papillomavirus-independent cervical cancer. Int J Gynecology Cancer. 2022; 32(1):1-7.
5. https://doi.org/10.1136/ijgc-2021-003014
7. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249.
8. https://doi.org/10.3322/caac.21660
10. Ministerio de Salud y Protección Social. Cuenta de Alto Costo. Día Mundial del Cáncer de Cervix 2022. [Internet]. [Consultado 07 Oct 2022]. Disponible en: https://cuentadealtocosto.org/site/dia-mundial-del-cancer-de-cervix-2022/.
12. Zaldívar G, Martín F, Sosa F, Ávila J, Lloret M, Román M, Vega G. Cáncer cérvicouterino y virus del papiloma humano. Rev. Chil. Obstet. ginecol. 2015;77(4):315-321.
13. https://doi.org/10.4067/S0717-75262012000400014
15. Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009; 384 (2):260-265.
16. https://doi.org/10.1016/j.virol.2008.11.046
18. Almonacid I, Almonacid C, Rosas S, Hernández E, González J. The current outlook of human papillomavirus and its association with digestive tract cancer. Revista Logos, Ciencia & Tecnología. 2021;13(1):129-143.
19. https://doi.org/10.22335/rlct.v13i1.1292
21. Rios M, Hernández M, Frontela M. Infecciones virales, posible factor de riesgo en cáncer de mama. Rev Cubana de Obstet Ginecol. 2016;42(3).
23. Hu Y, Ren S, He Y, Wang L, Chen C, Tang J, Liu W, Yiu F. Possible Oncogenic Viruses Associated with Lung Cancer. Onco Targets Ther. 2020;13:10651-66.
24. https://doi.org/10.2147/OTT.S263976
26. Toro A , Tapia L. Virus del papiloma humano (VPH) y cáncer. Medicina & Laboratorio. 2021; 25 (2):467-83.
27. https://doi.org/10.36384/01232576.431
29. Ferreira D, Tayyar Y, Idris A, MacMillan N. A "hit-and-run" affair-A possible lind for cancer progression in virally driven cancers. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188476.
30. https://doi.org/10.1016/j.bbcan.2020.188476
32. Lees B, Erickson B, Huh W. Cervical cancer screening: evidence behind the guidelines. Am J Obstet Gynecol. 2016;214(4): 438-43.
33. https://doi.org/10.1016/j.ajog.2015.10.147
35. Pereira J, Gaviria L, Zea S, Jaramillo P, Bedoya A. Descripción de pruebas moleculares en el diagnóstico del virus ZIKA en el periodo 2008-Febrero 2018. Revisión sistemática. NOVA. 2018;16(30):81-93.
36. https://doi.org/10.22490/24629448.2838
38. Guirou E, Schindler T, Hosch S, Donfack O, Yoboue C, Krähenbühl S, et al. Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic tests. Sci Rep. 2020;10(1):12305.
39. https://doi.org/10.1038/s41598-020-69268-5
41. Hamont D, Ham M, Bakkers J, Massuger L, Melchers W. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol. 2006;44(9):3122-9.
42. https://doi.org/10.1128/JCM.00517-06
44. Iriarte G, Orjuela J, Osorio W, Jiménez L. Detección de ARNm de oncoproteínas E6/E7 del Virus del Papiloma Humano en cáncer de cuello uterino. Acta bioquim. clín. latinoam. 218;52(3):361-72.
46. Saslow D, Solomon D, Lawson H, Killackey M, Kulasingam S, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Ca Cancer J Clin. 2012;62(3):147-72.
47. https://doi.org/10.3322/caac.21139
49. Domínguez S, Perdomo T, Aguilar K, Hernández M. Infección por el virus del papiloma humano en adolescentes y adultas jóvenes. Rev Cubana de Obstet Ginecol. 2018; 44(1):1-13.
51. Benard V, Watson M, Castle P, Saraiya M. Cervical carcinoma rates among young females in the United States. Obstet Gynecolo. 2012;120(5): 1117-23.
52. https://doi.org/10.1097/AOG.0b013e31826e4609
54. Pilleron S, Cabasag C, Ferlay J, Bray F, Luciani S, Almonte M, et al. Cervical cancer burden in Latin America and the Caribbean: Where are we? Int J Cancer. 2020; 147(6):1638-1648.
55. https://doi.org/10.1002/ijc.32956
57. Fleites Y, González M, Vásquez V, González A, Enríquez I, Leyva I. Lesiones de cuello uterino en mujeres menores de 25 años. Revista Electrónica de las Ciencias Médicas en Cienfuegos. 2011; 9(6): 22-28.
59. Ruiz R, Serrano M, Ruiz E, Mantilla R, Valdivieso N, Olivera M, et al. Características clínico-patológicas y sobrevida en mujeres jóvenes con cáncer cervical: análisis retrospectivo del instituto nacional de enfermedades neoplásicas. Rev Peru Med Exp Salud Publica. 2017;34(2):218-27.
60. https://doi.org/10.17843/rpmesp.2017.342.2653
62. Sampedro C, Ríos L, Cardona J. Prevalencia de alteraciones preneoplásicas del cáncer de cuello uterino en un municipio del Norte de Antioquia-Colombia, 2008-2012. Med Arh.2014;10(1):1-10.
64. Arango M. Tendencias temporales del cáncer de cuello uterino invasivo en mujeres entre 20 y 39 años en Manizales, Colombia. 2003-2018. Revista Médica Risaralda. 2021;27(1):21-27.
65. https://doi.org/10.22517/25395203.24621
67. Arbeláez A, Carreño C, Coñazos L, Castillo A. Implementación de la nueva guía práctica clínica para la detección y manejo de lesiones precancerosas de cuello uterino en mujeres de la ciudad de Cali, Colombia. Infectio. 2020;24(1):20-26.
68. https://doi.org/10.22354/in.v24i1.823
70. Zhang J, Zhao Y, Dai Y, Dang L, Ma L, Yang C, et al. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China. JAMA Oncol. 2021; 7(2):263-270.
71. https://doi.org/10.1001/jamaoncol.2020.6575
73. Acosta S, Ibáñez E, Alfonso A, Cifuentes L, Gamba S, Mojica C, et al. Conductas de Salud y Factores de Riesgo en la Salud Sexual y Reproductiva de una Población Universitaria. NOVA. 2010;8(13):33-43.
74. https://doi.org/10.22490/24629448.437
76. Blatt A, Kennedy R, Luff R, Austin R, Rabin D. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288.
77. https://doi.org/10.1002/cncy.21544
79. Perkins R, Guido R, Castle P, Chelmow D, Einstein M, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020; 24(2):102-131.
80. https://doi.org/10.1097/LGT.0000000000000525
82. Biesaga B, Janecka A, Mucha A, Adamczyk A, Szostek S, Słonina D, et al. HPV16 detection by qPCR method in relation to quantity and quality of DNA extracted from archival formalin fixed and paraffin embedded head and neck cancer tissues by three commercially available kits. J Virol Methods. 2016; 236:157-163.
83. https://doi.org/10.1016/j.jviromet.2016.07.021
85. Božić L, Jovanović T, Šmitran A, Janković M, Knežević A. Comparison of HPV detection rate in formalin-fixed paraffin-embedded tissues of head and neck carcinoma using two DNA extraction kits and three amplification methods. Eur J Oral Sci. 2020; 128(6):501-507.
86. https://doi.org/10.1111/eos.12746
88. Schwarz G, Sánchez C, Moreno N, Morató M, Martín S, Javierre A, et al. Infectious Disease Prevention Group. Update on vaccines, 2020. Aten Primaria. 2020; 52 (2):70-92.
89. https://doi.org/10.1016/j.aprim.2020.08.001
91. Balachandra S, Kusin S, Lee R, Blackwell J, Tiro J, Cowell L, et al. Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. Cancer. 2021;127(6):850-64.
92. https://doi.org/10.1002/cncr.33221
94. Trigg R, Martinson L, Parpart-Li S, Shaw J. Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. Heliyon. 2018;4(7):1-24.
95. https://doi.org/10.1016/j.heliyon.2018.e00699